Delving into the Latest Updates on Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology) with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms-

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Beijing Tuohua Weiye Biotechnology Co., Ltd.

Active Organization

Beijing Tuohua Weiye Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估MAK免疫细胞治疗晚期或复发性实体瘤患者（晚期肝细胞癌为主）的安全性、耐受性。次要目的：评估MAK免疫细胞治疗晚期或复发性实体瘤患者（晚期肝细胞癌为主）的抗肿瘤初步有效性；评估MAK免疫细胞治疗晚期或复发性实体瘤患者（晚期肝细胞癌为主）的多次给药的药效动力学（PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of MAK immunotherapy in patients with advanced or recurrent solid tumors (primarily advanced hepatocellular carcinoma). Secondary objectives: To evaluate the preliminary antitumor efficacy of MAK immunotherapy in patients with advanced or recurrent solid tumors (primarily advanced hepatocellular carcinoma); to evaluate the pharmacodynamic (PD) characteristics of multiple doses of MAK immunotherapy in patients with advanced or recurrent solid tumors (primarily advanced hepatocellular carcinoma).

Start Date24 Feb 2026

Sponsor / Collaborator

Beijing Tuohua Weiye Biotechnology Co., Ltd.

100 Clinical Results associated with Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology)

Login to view more data

100 Translational Medicine associated with Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology)

Login to view more data

100 Patents (Medical) associated with Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology)

Login to view more data

100 Deals associated with Mixed activated killer (MAK) immune cells(Beijing Tuohua Weiye Biotechnology)

Login to view more data